Drugs for Treatment of Partial Onset Seizures: Full Extrapolation of Efficacy from Adults to Pediatric Patients 2 Years of Age and Older

Guidance for Industry

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)

September 2019
Clinical Pharmacology/Clinical
Drugs for Treatment of Partial Onset Seizures: Full Extrapolation of Efficacy from Adults to Pediatric Patients 2 Years of Age and Older

Guidance for Industry

Additional copies are available from:

Office of Communications, Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration
10001 New Hampshire Ave., Hillandale Bldg., 4th Floor
Silver Spring, MD 20993-0002
Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353; Email: druginfo@fda.hhs.gov
https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs
TABLE OF CONTENTS

I.  INTRODUCTION............................................................................................................. 1
II.  BACKGROUND ............................................................................................................... 1
III. DEVELOPMENT CONSIDERATIONS........................................................................ 2
    A.  Formulation Development.......................................................................................... 2
    B.  Efficacy Considerations............................................................................................ 2
    C.  Clinical Pharmacology and Dosing Considerations......................................................... 2
    D.  Safety Considerations .................................................................................................. 3
I. INTRODUCTION

This guidance provides recommendations to sponsors on the clinical development of drugs for the treatment of partial onset seizures (POS) in pediatric patients. Specifically, this guidance addresses FDA’s current thinking regarding clinical development programs that can support extrapolation of the efficacy of drugs approved for the treatment of POS in adults to pediatric patients 2 years of age and older. This guidance does not address clinical development programs for the treatment of POS in pediatric patients younger than 2 years of age. This guidance does not address the development of drugs to treat other types of seizures.

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.

II. BACKGROUND

Historically, because evidence to support an extrapolation approach was not available, FDA has required, under section 505(d) of the Federal Food, Drug, and Cosmetic Act, that sponsors establish efficacy for the treatment of POS in pediatric patients by performing one or more adequate and well-controlled clinical studies in pediatric patients. The doses in these pediatric studies were generally based on body weight and age, in an effort to attain blood concentrations similar to those found to be effective in adults. Selection of doses was also informed by safety and tolerability data from open-label studies in the pediatric population.

---

1 This guidance has been prepared by the Division of Neurology Products and the Division of Clinical Pharmacology I in the Center for Drug Evaluation and Research at the Food and Drug Administration.
Efficacy can be extrapolated from adults to pediatric patients when it is reasonable to assume that children, compared with adults, have a similar progression of disease, similar response of disease to treatment, and similar exposure-response relationship. After excluding children with POS associated with epileptic encephalopathies, such as Lennox-Gastaut syndrome, the pathophysiology of POS appears similar in adults and pediatric patients 2 years of age and older. Clinical studies of drugs for the treatment of POS in pediatric patients, some of which enrolled patients as young as 2 years of age, have shown a response to treatment (reduction in seizure frequency) similar to the response to treatment seen in adults. Systematic and quantitative analyses conducted by FDA, using data from clinical studies of drugs approved for the treatment of POS in both adults and pediatric patients, have shown that the relationship between exposure and response (reduction in seizure frequency) is similar in adults and pediatric patients 4 years of age and older. These drugs have a variety of putative mechanisms of action. These analyses and observations have allowed FDA to conclude that the efficacy of drugs approved for the treatment of POS can be extrapolated from adults to pediatric patients 2 years of age and older.

III. DEVELOPMENT CONSIDERATIONS

A. Formulation Development

Children may differ from adults in many aspects of pharmacotherapy, including feasibility of routes of drug administration, drug-related toxicity, and taste preferences. It is therefore essential for sponsors to formulate pediatric drugs to best suit a child’s age, size, and physiologic condition. FDA encourages sponsors to explore innovative approaches to pediatric formulation development and testing.

B. Efficacy Considerations

As noted above, FDA has concluded that the efficacy of drugs approved for the treatment of POS in adults can be extrapolated to pediatric patients 2 years of age and older. This conclusion does not apply to the treatment of POS in pediatric patients younger than 2 years of age or to the treatment of other types of seizures.

C. Clinical Pharmacology and Dosing Considerations

To support extrapolation, blood concentrations of active drugs and metabolites should be obtained from an adequately designed pharmacokinetic and tolerability study in patients 2 to 16 years of age. The study should include an appropriate distribution of pediatric patients across this age range.

---

2 See the guidance for industry *Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products* (May 1998). See also the pediatric study planning and extrapolation algorithm in the draft guidance for industry *General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products* (December 2014). When final, this guidance will represent FDA’s current thinking on this topic. For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/regulatory-information/search-fda-guidance-documents.

age range and be designed to characterize adequately the acute tolerability over a range of doses that covers drug concentrations known to be effective in adults.

Simulations should be performed to select doses expected to achieve exposures similar to those in adults. The sample size and sampling scheme should be planned carefully to enable characterization of pharmacokinetics with adequate precision.\(^4\) Pharmacokinetic data from that study should be used to determine pediatric dose and regimens that provide drug exposure similar to that known to be effective in adult patients with POS. Sponsors should share the results of this analysis with FDA before initiating the open-label safety studies described below.

**D. Safety Considerations**

Safety data generally cannot be extrapolated from adults to children. Therefore, sponsors should conduct clinical studies to characterize adequately the safety of the drug in pediatric patients 2 years of age and older with POS, with all ages well-represented. Such studies can be open-label in design. In general, a minimum of 100 pediatric patients should be exposed to the drug for at least 6 months of treatment, although the specific study characteristics should be determined on a case-by-case basis, depending on the expected and emerging safety profile of the drug. Dosing levels in these safety studies should be at or above those determined to be effective in the pediatric population, based on the extrapolation described above. Blood concentrations of the drug and its active major metabolites should be quantified whenever severe or serious adverse events occur in patients enrolled in the study.